Futatsuki K, Shimada S, Kanda Y, Ishibashi I, Sendai H, Akazawa S, Hattori M
Gan To Kagaku Ryoho. 1984 May;11(5):1112-5.
SF-SP capsules containing sustained release granules of tegafur were orally administered 800 mg, b.i. d. for more than 4 weeks in 20 cases of advanced cancer, 11 of whom were evaluable (stomach 7, colon 1, liver 1, bile 1 and pancreas 1). The evaluation of antitumor effects was based on criteria of the Japan Society for Cancer Therapy, which are are almost the same as those of WHO. One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks. Toxicities were anorexia, nausea and vomiting, diarrhea and stomatitis, one case each of anorexia, and nausea and vomiting occurred within 10 days after SF-SP administration. No bone marrow depression, hepatic and renal disorders occurred after long-term SF-SP administration. SF-SP seems to be useful in the treatment of patients with gastric cancer.
含替加氟缓释颗粒的SF-SP胶囊，以800mg的剂量口服，每日2次，对20例晚期癌症患者进行了4周以上的给药治疗，其中11例可进行评估（胃癌7例、结肠癌1例、肝癌1例、胆管癌1例和胰腺癌1例）。抗肿瘤效果的评估依据日本癌症治疗协会的标准，该标准与世界卫生组织的标准几乎相同。7例胃癌患者中有1例获得部分缓解，缓解持续时间为40周。毒性反应为厌食、恶心和呕吐、腹泻以及口腔炎，在服用SF-SP后10天内分别有1例出现厌食、恶心和呕吐。长期服用SF-SP后未出现骨髓抑制、肝肾功能障碍。SF-SP似乎对胃癌患者的治疗有用。
